乳腺癌依西美坦耐药细胞株的建立及耐药机制的初步研究  

Establishment of a exemestane-resistant human breast cancer cell line and investigation of its resistance mechanism

作　　者：胡丽霞[1] 袁媛 杜瀛瀛[1] 潘跃银[1] 

机构地区：[1]安徽医科大学第一附属医院肿瘤科,合肥233022 [2]合肥市滨湖医院中心实验室,合肥230601

出　　处：《安徽医科大学学报》2012年第12期1404-1407,共4页Acta Universitatis Medicinalis Anhui

基　　金：安徽省年度重点科研计划项目(编号:11070403061);安徽省年度科研计划项目(编号:09020303042)

摘　　要：目的建立稳定传代的抵抗依西美坦的人乳腺癌细胞株MCF-7/EXE,并探讨其可能耐药机制。方法采用体外浓度梯度递增的诱导方法建立依西美坦获得性MCF-7/EXE耐药细胞株;采用MTT法计算出MCF-7和MCF-7/EXE的半数抑制浓度(IC50)和耐药倍数(RI);用流式细胞仪技术检测其细胞周期;用Western blot方法检测p-ERK和Bcl-2蛋白的表达。结果依西美坦对MCF-7和MCF-7/EXE的IC50分别为(27.06±3.47)、(128.43±0.91)μmol/L,RI为4.75(P<0.05)。这两种细胞株的G0/G1期、S期差异有统计学意义(P<0.05),G2/M期差异无统计学意义。与亲本细胞相比,MCF-7/EXE中p-ERK和Bcl-2蛋白表达升高。结论成功建立一株耐依西美坦的人乳腺癌细胞株MCF-7/EXE,适合于乳腺癌中依西美坦耐药机制的研究。Objective To establish stable MCF-7 cell lines resistant to exemestane and describe its resistant mech- anisms. Methods Using gradual increase of exemestane concentrations in culture, a exemestane-resistant human breast carcinoma cell hne （MCF-7/EXE） was established in vitro. The ICs0 and resistance index （RI）of MCF-7 and MCF-7/EXE cell lines were measured by MTT. Cell cycles were assayed with flow cytometry method. Western blot analysis was used to investigate the expression of ERK activation and Bcl-2. Results The lCs0 increased from （ 27.06 ＋ 3.47 ） t^mol/L in MCF-7 to（ 128.43 _＋ 0. 91 ） txmoL/L in MCF-7/EXE and the RI was 4. 75 （P 〈 0.05 ）. The cell cycles of G0/G1 period and S period had a significant difference between these two cell lines（ P 〈0. 05 ）, the G2/M period change was not obvious. Compared with its parental cell line, the expression of ERK activation and Bcl-2 was significantly increased in MCF-7/EXE cell line. Conclusion MCF-7/EXE, the exemestane resistant phenotype, is suitable cell model for studying exemestaue resistant in breast cancer.

关 键 词：依西美坦 乳腺癌 耐药 

分 类 号：R737.9[医药卫生—肿瘤]